文献速递白血病造血干细胞移植与细胞治疗

儿童T细胞急性淋巴细胞白血病微小残留病的现状与展望

[Current situation and prospect of minimal residual disease in pediatric T cell acute lymphoblastic leukemia].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2025-01-01

儿童T细胞急性淋巴细胞白血病(T-ALL)侵袭性强、治疗复杂,微小残留病(MRD)仍是影响预后的关键因素。本文综述了定量PCR、多参数流式细胞术和高通量测序等MRD检测方法,以及MRD监测在多药联合化疗与造血干细胞移植中的临床意义,并探讨了用MRD衡量新疗法反应性与有效性的应用及未来方向。

要点

  • 儿童T-ALL侵袭性强、治疗复杂,MRD存在仍是影响预后的重要因素。
  • 定量PCR、多参数流式细胞术和高通量测序可精确检测MRD,助力个体化精准治疗。
  • MRD监测在多药联合化疗与造血干细胞移植中具有临床意义,并可用于衡量新疗法反应性。

核心结论

  • 儿童T-ALL治疗效果已显著提升,但MRD仍是影响预后的重要因素,精确检测MRD有助于实现个体化精准治疗。

研究设计与样本

  • 综述,围绕儿童T-ALL的MRD检测方法、多药联合化疗与造血干细胞移植中MRD监测评估的临床意义,以及用MRD衡量新疗法反应性与有效性进行汇总。

主要发现

  • 定量PCR、多参数流式细胞术和高通量测序技术的临床应用已能够对MRD进行精确检测。
  • MRD监测与评估在多药联合化疗和造血干细胞移植中具有临床意义。
  • MRD可用于衡量近期T-ALL中新疗法的反应性与有效性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pediatric T-cell acute lymphoblastic leukemia (T-ALL) has been attracted much attention due to its high aggressiveness and complexity of treatment. Recently, with the development of technology and clinical research, the curative effect of T-ALL in children has been significantly improved. However, the presence of minimal residual disease (MRD) is still a key factor affecting the outcomes of children with T-ALL. With the continuous development of detection methods, the clinical applications of real-time quantitative PCR, multi-parameter flow cytometry, and high-throughput sequencing technology, MRD can be detected accurately to achieve personalized and precise treatment for each patient. The purpose of this article is to review the current detection methods of MRD in T-ALL, the clinical significance of MRD monitoring and evaluation in multi-agent combined chemotherapy and hematopoietic stem cell transplantation, and applying MRD to measure the responsiveness and effectiveness of new therapies in recent T-ALLs. Research directions and potential treatment strategies in the near future were also proposed. 儿童急性T淋巴细胞白血病(T-ALL)因其高侵袭性和治疗复杂性而备受关注。近年来,随着医疗技术的进步和研究的深入,儿童T-ALL的治疗效果已得到显著提升。然而,微小残留病(MRD)的存在仍然是影响儿童T-ALL预后的重要因素。随着检测方法的不断发展,目前定量PCR、多参数流式细胞术和高通量测序技术的临床应用,已经能够对MRD进行精确地检测,从而实现患者个体化的精准治疗。本文旨在综述当前儿童T-ALL MRD的检测方法、多药联合化疗与造血干细胞移植中MRD监测与评估的临床意义,以及应用MRD衡量近期T-ALL中新疗法的反应性与有效性,并展望未来的研究方向和潜在的治疗策略。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Niu FF, Gao C. [Current situation and prospect of minimal residual disease in pediatric T cell acute lymphoblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2025. PMID: 40059690. doi:10.3760/cma.j.cn121090-20240701-00239

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。